Cargando…

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study

PURPOSE: To investigate the tolerability and the effects of the β-3-adrenoceptor-agonist mirabegron on urinary incontinence and urodynamic parameters in patients with chronic neurogenic detrusor overactivity (NDO). PATIENTS AND METHODS: The patient database of a spinal cord injury rehabilitation cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krebs, Jörg, Pannek, Jürgen, Rademacher, Franziska, Wöllner, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250696/ https://www.ncbi.nlm.nih.gov/pubmed/32548077 http://dx.doi.org/10.2147/RRU.S253713

Ejemplares similares

Clinical usefulness of urine cytology in the detection of bladder tumors in patients with neurogenic lower urinary tract dysfunction
por: Pannek, Jürgen, et al.
Publicado: (2017)

Botulinum Toxin in Neurogenic Detrusor Overactivity
por: D'Ancona, Carlos Arturo Levi, et al.
Publicado: (2012)

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study
por: Baka‐Ostrowska, Małgorzata, et al.
Publicado: (2021)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions
por: Pannek, Jürgen, et al.
Publicado: (2017)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Hui, C, et al.
Publicado: (2016)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury
por: Chung, Yeun Goo, et al.
Publicado: (2015)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience
por: Allison, Sara J., et al.
Publicado: (2018)

AB206. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Chen, Hui, et al.
Publicado: (2016)

Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity
por: Ballouhey, Quentin, et al.
Publicado: (2015)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
por: Ferreira, Ana, et al.
Publicado: (2023)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Immunomodulation for primary prevention of urinary tract infections in patients with spinal cord injury during primary rehabilitation: protocol for a randomized placebo-controlled pilot trial (UROVAXOM-pilot)
por: Krebs, Jörg, et al.
Publicado: (2021)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model
por: Biardeau, Xavier, et al.
Publicado: (2017)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
por: Lombardi, Giuseppe, et al.
Publicado: (2017)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
por: Yuan, Hejia, et al.
Publicado: (2017)

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study
por: Maignel, Jacquie, et al.
Publicado: (2022)

TASCI—transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial
por: Birkhäuser, Veronika, et al.
Publicado: (2020)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Semiconditional Electrical Stimulation of Pudendal Nerve Afferents Stimulation to Manage Neurogenic Detrusor Overactivity in Patients with Spinal Cord Injury
por: Lee, Young-Hee, et al.
Publicado: (2011)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_uaiivsa8audotr7h9kqi2s96p8